Archives

FDA Grants Fast Track Designation for CS-1103, a First-in-class Small Molecule to Reverse Acute Intoxication from Fentanyl

B CAMBRIDGE, Mass., May 5, 2026 /PRNewswire/ — Clear Scientific Inc., a clinical stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration… Login to continue reading Login…

Read MoreFDA Grants Fast Track Designation for CS-1103, a First-in-class Small Molecule to Reverse Acute Intoxication from Fentanyl

Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month

B Longstanding collaborations with AIM at Melanoma, the Melanoma Research Foundation, The Skin Cancer Foundation, IMPACT Melanoma and The Sun Bus continue to advance awareness and education throughout May FRIENDSWOOD, Texas, May 5,… Login to continue reading Login…

Read MoreCastle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month

New ASHA-Lantern Texting Program Provides Expert Advice for Handling Picky Eating and Other Feeding Challenges

B Free Program Conveniently Delivers Tips to Caregivers’ Smartphones ROCKVILLE, Md., May 5, 2026 /PRNewswire/ — Feeding challenges are among the most common—and stressful—issues that families… Login to continue reading Login…

Read MoreNew ASHA-Lantern Texting Program Provides Expert Advice for Handling Picky Eating and Other Feeding Challenges

Lilly’s Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years

B In LUCENT-3, more than 60% of patients who achieved disease clearance at one year maintained it after four years of continuous Omvoh treatment Disease… Login to continue reading Login…

Read MoreLilly’s Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years